Chemists reveal novel biocatalysts for bioactive alkaloid synthesis
alkaloids are natural nitrogen-containing compounds produced by plants and microbes. These molecules, such as morphine and quinine, are important human medicines. Alkaloids are typically polycyclic in nature. While the polycyclic characteristics are important for their bioactivities, these features impede their chemical syntheses in the laboratory and their applications as pharmaceuticals.
Hapalindole-type alkaloids are renowned for potent antimicrobial and antitumor activities. These alkaloids are typically tricyclic and tetracyclic in nature and synthetically challenging to access in the laboratory for drug discoveries.
The group led by Xinyu Liu, an assistant professor of chemistry within Pitt's Kenneth P. Dietrich School of Arts and Sciences, disclosed a novel family of enzymes (protein catalysts) that can direct the biogenetic assembly of the polycyclic scaffolds in the hapalindole-type alkaloids.
Liu and postdoctoral associate Qin Zhu utilized bacterial E. coli as a heterologous host and demonstrated that the proteins encoded by previously uncharacterized U-family genes in several hapalindole pathways are novel cyclization biocatalysts that can morph simple acyclic precursors into three distinct hapalindole scaffolds. Bioinformatic analysis further revealed each hapalindole producer often encodes one or several copies of U genes to direct the divergent assembly of several hapalindoles in the same producers.
Their work provides conclusive evidence on the biochemical basis for the origin of early structural diversity in hapalindole-type natural products. "With the U-family proteins characterized as a novel family of cyclization enzymes, we now have the complete biocatalyst tool sets in hand to synthesize these molecules in our laboratory. After six years of efforts and several groundbreaking works generated from my lab on the biosynthesis of hapalindole-type alkaloids, we finally have a chemoenzymatic platform to advance these remarkable molecules for drug discoveries. It is a great feeling and exciting time for us," said Liu.
Original publication
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Algeta appoints Dr. Donald Coppen as Business Development Director
New coronavirus related to viruses from bats
Analytica 2022 wowed the laboratory industry - analytica extended: digital extension through July 8
Novel process for DNA labeling
Alzheimer’s Drug PRI-002 Receives EMA Approval for Phase II Trial
Wolff's_law
Incurable liver disease may prove curable - Research has found a drug that can spur liver regeneration in Alagille syndrome: researcher taking Steps to form a start-up company
Thomson Reuters Predicts Nobel Laureates
Existing drug preserves insulin production in new Type 1 diabetes cases
Illumina and Wellcome Trust Sanger Institute Announce Completed Genome for Endangered Tasmanian Devil - Uncovering Mutations Found in Deadly Transmissible Cancer Could Help Conservation Efforts
When mothers shut down the fathers’ genes in the embryo - “With our work, we were able to highlight a unique aspect of biology, a slice of nature’s broad diversity”
